A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
NCT07506863 · ENERGIZEKids-T Phase 3Recruiting
- Lead sponsor
- Agios Pharmaceuticals, Inc. (Industry)
- Enrollment
- 54 (estimated)
- Start date
- 24 Sep 2026
- Primary completion
- Jun 2029 (estimated)
- Study completion
- 1 Jun 2032
- Last update posted
- 29 Oct 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- Mitapivat Matched Placebo Drug
- Mitapivat Drug
Conditions and primary outcome
- Transfusion-dependent Alpha-Thalassemia
- Transfusion-dependent Beta-Thalassemia
Primary outcome
Percentage of Participants Who Achieved Transfusion Reduction Response (TRR) Through Week 48 (Baseline, through Week 48)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT07506863.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT07506863 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.